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LETTER TO THE EDITOR
Pruritus in patients with amyopathic 
dermatomyositis
Dimitri Poddighe1* , Zaure Mukusheva2 and Maikesh Assylbekova1,2
Abstract 
Amyopathic dermatomyositis has been associated with the exposure to several drugs: the article by Jeimy et al. 
described the onset of this uncommon disease in a patient treated with omalizumab. Paradoxically, this patient 
complained of an intense pruritus and this finding has been reported by several authors observing patients with 
amyopathic dermatomyositis.
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To the Editor,
We read with great interest the case report by Jeimy et al. 
[1], describing the onset of amyopathic dermatomyositis 
(aDM) in an adult patient receiving omalizumab therapy 
for severe asthma. As highlighted by the authors, this is 
the first case report of DM associated with the biological 
anti-IgE therapy, namely omalizumab, which is currently 
approved to treat unresponsive chronic spontaneous 
urticaria as well [1, 2]. Paradoxically, this clinical case was 
characterized with an intense pruritic dermatitis and, 
beyond the description of such a peculiar drug-disease 
association, it provides the opportunity to focus the 
attention on some clinical features of the “amyopathic” 
variant of DM, which is often difficult to be diagnosed. 
Indeed, delays in diagnosis can be due to the lack of clear 
clinical characteristics and typical biochemical changes.
Previously, we described a case of amyopathic juvenile 
DM (JDM) and, interestingly, we also noticed that 
important “erythematous, intensely pruritic cutaneous 
eruption” unresponsive to several drugs, as described 
by Jeimy et  al. [1]. Specifically, our patient received 
several courses of  H1-antihistamines (e.g. cetirizine, 
levocetirizine, loratadine, oxatomide) without achieving 
the complete control of pruritus: indeed, she required 
intra-venous chlorphenamine several times and even 
received low-dose amitriptyline, as prescribed by the 
specialist in pain management. This clinical aspect has 
oriented our attention on pursuing a diagnosis of allergy 
for months, given that the typical clinical signs of JDM, 
such as heliotrope rash and Gottron’s papules, have 
appeared much later during the clinical course, namely 
10–12  months after the symptom onset. Similarly, our 
patient displayed neither significant abnormalities of 
muscle enzymes, nor specific autoantibody, but she 
responded to the immunosuppressive therapy and, in 
particular, to hydroxychloroquine, as a maintenance and 
steroid-sparing drug [3].
Other authors have reported this very pruritic aspect of 
skin manifestations in aDM. Concha et al. reported this 
feature as a frequent finding in their article that revisited 
the current diagnostic criteria for aDM. Indeed, these 
authors highlighted that pruritus has been considered in 
several classification criteria for aDM (e.g. Sontheimer 
1997, Dalakas 2003) and it is more pronounced in this 
rheumatic disease rather than others (e.g. systemic lupus 
erythematosus) [4–6].
Recently, Galimberti et  al. also reported intense 
pruritus in 55% of their study cohort, including 44 
patients diagnosed with aDM (who represented 18% of 
all their DM patients). Most of their patients (female/
male ratio = 10:1) were 50–70 years old at aDM diagnosis 
[7], but our case demonstrated that aDM can arise as 
juvenile form as well [3]. Interestingly, 19 out 24 of their 
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aDM patients (corresponding to > 75%) were not affected 
by any malignancy [7].
Therefore, patients with “amyopathic” DM/JDM can 
develop a dermatosis characterized with very intense 
itching, which may mislead the diagnosis toward allergy 
diseases for long time and, as a consequence, delay the 
correct diagnosis and therapy.
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